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1. Introduction 
Neurally mediated syncope syndromes involve autonomic reflexes causing bradycardia 
and/or hypotension resulting in a transient loss of consciousness(Brignole et al., 2004). 
These episodes can result in injuries and emotional stress. Recurrent vasovagal syncope can 
have a significant detrimental effect on the quality of life comparable to chronic disease 
patients with chronic back pain or rheumatoid arthritis(Linzer et al., 1991; Rose, Koshman, 
Spreng, & Sheldon, 2000). Hence management strategies have targeted vasodepression and 
bradycardia. Pacing has been a tempting solution that treats the cardioinhibitory response.  
2. Vasovagal syncope 
Vasovagal syncope is one of the common causes of syncope and a common reason for 
emergency room encounters(Savage, Corwin, McGee, Kannel, & Wolf, 1985). Vasovagal 
syncope is seen in younger patients and the reflex may have triggers such as sight of blood, 
venipuncture, or prolonged standing(Brignole et al., 2004). Some patients may have a 
prodrome of nausea and diaphoresis prior to loss of consciousness due to hypotension and/or 
bradycardia. Usually the syncopal episode last less than a minute but accompanying nausea, 
diaphoresis, and pallor can last longer. Many patients do not have a prodrome sufficiently 
long upon which to act, and therefore are unable to use preventive techniques such as 
counterpressure maneuvers or sitting/lying down to avoid or minimize a full episode. Unlike 
patients with cardiac or neurologic cause for syncope, patients with vasovagal syncope have 
no increased risk of cardiovascular morbidity or mortality (Soteriades et al., 2002). Hence in 
patients with vasovagal syncope preventing injury and maintaining a good quality of life are 
the primary goals for management(Kuriachan & Sheldon, 2008). 
3. Initial pacing studies for vasovagal syncope 
Bradycardia has long been recognized as a component of vasovagal syncope(Sharpey-Schafer, 
1956). In recent years, bradycardia was seen during tilt table test studies in patients with 
vasovagal syncope during the induced episodes(Mosqueda-Garcia et al., 1997). Bradycardic 
problems have also been detected by pacemaker and implantable loop recorders during clinic 
episodes of vasovagal syncope(Krahn, Klein, & Yee, 1997). This suggested that pacing could 
prevent vasovagal syncope by treating the bradycardia component. This was initially looked 
at in patients with tilt table induced syncope associated with bradycardia(Fitzpatrick, 
Theodorakis, Ahmed, Williams, & Sutton, 1991). These patients underwent repeat tilt table test 
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with temporary pacing. This prevented syncope in over half the patients although they still 
experienced vasovagal symptoms and presyncope. The results of this study should also be 
interpreted with caution since repeated tilt table testing can have a training effect and may 
reduce syncopal episodes(Reybrouck, Heidbuchel, Van De Werf, & Ector, 2002). Also the 
hemodynamic changes seen on tilt table induced syncopal episodes may not correlate with 
clinical episodes(Menozzi et al., 1993).  
Initial observational studies seemed to show benefit with pacing as a treatment for 
vasovagal syncope(Sheldon, Koshman, Wilson, Kieser, & Rose, 1998; Petersen et al., 1994; 
Benditt et al., 1997). These initial studies were mainly a sequential design, with no placebo 
group, and included highly symptomatic patients, who received a pacemaker. Open label 
studies then followed which also showed impressive results with pacing. The North 
American Vasovagal Pacemaker Study (VPS) randomized 54 vasovagal syncope patients to 
a pacemaker or optimal medical treatment(Connolly, Sheldon, Roberts, & Gent, 1999a). 
Impressive results, as shown in Figure 1, were seen with 19/27 in the medical treatment 
group and only 6/27 in the pacemaker arm having one or more recurrences of syncope. The 
Vasovagal Syncope International Study (VASIS) randomized 42 syncope patients with 
cardioinhibitory responses on tilt table testing to pacemaker or medical therapy(Sutton et 
al., 2000). Again, an impressive reduction in syncope was seen, with only 5% in the 
pacemaker group and 61% in the medical therapy having syncope recurrence. Another open 
label study, Syncope Diagnosis and Treatment Study (SYDAT), randomized 93 syncope 
patients to a pacemaker or atenolol(Ammirati, Colivicchi, & Santini, 2001). This also showed 
a significant reduction in syncope with pacing (4.3%) versus atenolol (26%). Hence initial 
observational and open-label studies suggest a significant reduction in syncope recurrence 
with pacing with up to 87% relative risk reduction(Sud et al., 2007a; Connolly, Sheldon, 
Roberts, & Gent, 1999b). Summaries of the observational and randomized open-label pacing 
studies in vasovagal syncope are shown in Table 1. 
 
 
Fig. 1. Kaplan-Meier plot of time to first recurrence in VPS I of the 27 patients with 
pacemaker and the 27 patients without a pacemaker by intention-to-treat analysis. Figure 
from (Connolly et al., 1999a) 
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Study (year) Type of Study 
Tilt Testing 
part of 
inclusion 
Study Arms Results 
Sheldon et al. (1998) Observational Yes 
12 patients with VVS. Rate drop 
pacing in all patients 
No syncope in 
50% 
Peterson et al. (1994) Observational Yes 
37 patients with VVS. 35 had 
DDD and 2 had VVI 
No syncope in 
62% 
Benditt et al (1997) Observational No 
31 patients with VVS or CSS. 
Rate drop pacing in all patients 
No syncope in 
80% 
VPS I (1999) 
Open-label 
randomized 
Yes 
54 patients with VVS 
randomized to rate drop pacing 
or no implant 
85% relative 
risk reduction 
SYDAT (2001) 
Open-label 
randomized 
Yes 
93 patients with VVS 
randomized to ppm with rate 
drop response or to atenolol 
83 % reduction 
of syncope 
with pacing 
VASIS (2000) 
Open-label 
randomized 
Yes 
42 patients with VVS randomized 
to ppm with hysteresis and 23 
with no implant 
90% reduction 
of syncope 
with pacing 
VVS = vasovagal syncope, CSS = carotid sinus syncope, ppm = pacemaker 
Table 1. Summary of major open-label and observational studies for pacing in vasovagal 
syncope 
4. Pacemaker programming 
Various pacemaker settings have been tried in patients with vasovagal syncope. In general 
dual chamber (AV sequential) pacing is preferred, since both sinus and atrioventricular 
nodal function can be affected during a vasovagal episode. DDD pacing was compared to 
VVI and to sensing only (ODO) in 12 children with vasovagal syncope and found both 
modes of pacing to prevent syncope(McLeod, Wilson, Hewitt, Norrie, & Stephenson, 1999). 
All 12 were implanted with dual chamber pacemakers. Then programmed to ODO, VVI, 
and DDD with rate drop response for four month periods. Parents and patients were 
blinded to the pacemaker mode. Physician analyzing the results were blinded to patient and 
pacemaker mode. Even though both pacing modes prevented syncope, DDD was better 
than VVI for reducing presyncopal events.  
Rate-changing programming has also been examined including rate hysteresis, rate 
smoothing, and rate drop response. The goals of these programming strategies are to treat the 
bradycardia and also to compensate for the hypotensive/vasodepressive response. Rate 
hysteresis triggers pacing at a higher rate when the intrinsic heart rate falls below a preset rate. 
Rate smoothing prevents sudden changes in heart rate by pacing when there is an abrupt drop 
in intrinsic heart rate even in just 1-2 beats. (This is also used in patients with atrial fibrillation.) 
Rate drop response, the most sophisticated of the three, results in high rate pacing for a few 
minutes when a drop in native heart rate is detected. This hopes to achieve pacing support that 
can overcome bradycardia and hypotension. Rate response programming has been used in 
many syncope studies including VPS and VPS II. One study compared DDD with rate drop 
response to DDI with rate hysteresis in vasovagal syncope(Ammirati et al., 1998). This study 
randomized 20 vasovagal syncope patients with cardioinhibitory response during tilt testing 
to rate drop response or rate hysteresis. During the 17 month follow up, no patients with rate 
drop response had syncope but 3 of 8 in the rate hysteresis group had recurrence of syncope. 
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Hence rate drop response was found to be more effective. Recent studies have also looked at 
closed loop stimulation (CLS). In closed loop stimulation variation of intracardiac impedance 
is tracked every beat, so that contractility changes can be detected in the early phase (prior to 
changes in heart rate) of a vasovagal episode and dual chamber pacing is activated(Occhetta, 
Bortnik, Audoglio, & Vassanelli, 2004a), as shown in Figure 2. This early initiation of pacing is 
believed to not only treat the bradycardic response that may follow but also overcome the 
transient hypotension. The INVASY trial randomized 55 patients with vasovagal syncope and 
positive tilt test to a CLS pacemaker or DDI and found CLS to be effective in preventing 
syncope over two-year follow-up period(Occhetta et al., 2004a). None of the patients had 
recurrences of syncope while in a CLS mode. However both groups had a reduction in syncope, 
likely due to a placebo effect. The recently completed, but not published, SCANSYNC study 
also used CLS pacing, described below. A preceding single blind cross-over study of 23 
patients used a microaccelerator-equipped ventricular pace/sense leads (Sorin Biomedica, 
Saluggia, Italy) with a sensor at the tip that measures peak endocardial acceleration that 
correlates with measurements of left ventricular contractility(Deharo et al., 2003). This study 
compared standard DDI pacing to a rate adaptive (DDDR) specialized pacing system with a 
microaccelerometer in the right ventricular lead to detect myocardial contractivity. Both 
modalities were found to decrease syncopal episodes; in addition, the contractility-driven 
DDDR might have an additive benefit to conventional DDI pacing (Deharo et al., 2003).  
 
 
Fig. 2. Autonomic nervous system (ANS) monitors cardiac output (CO) via the mean arterial 
blood pressure (MABP). Cardiac output is a product of heart rate (HR) and stroke volume 
(SV). Myocardial contraction dynamics are monitored and changes detected early on by the 
closed loop stimulation pacemaker. Which enables the CLS pacemaker to provide heart rate 
changes help improve cardiac output. Figure taken from 
http://www.biotronik.com/en/in/1088 (c) Biotronik. Reproduced with permission from 
BIOTRONIK 
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5. Randomized, double blind studies comparing active pacing to sensing 
only 
The great success of the initial studies raised the possibility a placebo effect with implant of 
a pacemaker for treatment of vasovagal syncope. Hence the first randomized, multicenter, 
double blinded study was designed and completed. VPS II, in which all 100 patients 
received pacemakers but were randomized to dual chamber pacing with rate drop sensing 
or sensing only(Connolly et al., 2003). After six months of follow up, there was no significant 
benefit with pacing and showed a 40% cumulative risk of syncope in the sensing group and 
31% in the pacing group. This was also confirmed in a smaller study that included 29 
patients with recurrent tilt-induced vasovagal syncope and one relapse after tilt testing 
(SYNPACE)(Raviele et al., 2004). In this study, patients all received a pacemaker and then 
were randomized to pacing or no pacing. Results of the first interim analysis and VPS II 
stopped this trial prematurely. They were unable to show a benefit with active pacing in 
preventing syncope. 
A recent meta-analysis examined the role of pacing in vasovagal syncope(Sud et al., 2007b). 
Nine randomized trials were looked at in the meta-analysis, which included open label, 
single blind, and double blind trials. Interestingly, in contrast to open label trials, blinded 
trials for pacing in vasovagal syncope do not show a benefit, even in patients with marked 
cardioinhibitory response on tilt table testing(Sud et al., 2007a). Therefore, a cardioinhibitory 
response on tilt table testing probably is neither an appropriate surrogate marker for pacing 
studies, nor can it be used to predict patients who might respond to pacing.. The authors of 
the meta-analysis described that the benefits seen in open label, unblinded trials as being 
due to an expectation effect, by both patients and physicians. The authors of this meta-
analysis synthesized a unique comparison between “inactive” pacing and no treatment and 
found that the expectation response alone reduces the odds of syncope by 84% (Figure 3). 
 
Study (year) 
Number 
of 
Patients 
Type 
Tilt Testing 
part of 
inclusion 
Study Arms Results 
VPS II (2003) 100 
Double blind 
randomized
No 
Rate drop pacing vs 
ODO 
Pacing did not 
reduce risk of 
syncope 
SYNPACE 
(2004) 
29 
Double blind 
randomized
Yes DDD rate drop vs ODO 
Pacing did not 
reduce risk of 
syncope 
Deharo et al. 
(2003) 
23 
Single blind 
randomized 
crossover 
No 
Contractility driven 
DDDR vs DDI 
Both reduced 
syncope. Contractility 
driven may be better 
than DDI 
INVASY (2004) 50 
Single blind 
randomized 
crossover 
Yes 
DDD-CLS compared to 
DDI 
Both reduced 
syncope. CLS pacing 
seems to be better 
than DDI. 
Mcleod et al. 
(1999) 
12 
Double blind 
randomized
No DDD vs VVI vs ODO 
Pacing prevented 
syncope. DDD 
further reduced 
presyncope. 
Table 2. Randomized blinded studies in pacing for Vasovagal Syncope 
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Fig. 3. Odds ratios comparing active cardiac pacing versus no therapy, “inactive” pacing 
versus active pacing, and a synthesized “inactive” versus no therapy. Line at OR 1.0 
indicates no difference between the two groups. Estimates to the left of 1 represent 
treatment is better and estimates to the right represent control is better. Hence the bottom 
comparison represents the “expectation” effect. Figure from Sud et al 2007.  
6. Placebo effect in pacing for vasovagal syncope 
The placebo effect can be powerful and may be due to expectation effects of patients and 
health care providers, conditioning effects in patients, along with biases in patient assessment 
and reporting(Olshansky, 2007). Patients who receive pacemakers, due to the expense and 
invasive nature of the treatment, may be more willing to consider it as being a beneficial 
treatment for their problems. Healthcare workers who are involved in the care of these 
patients may not be conscious of biases they are exhibiting in assessment and reporting, and 
may also apparently observe a benefit from an ineffective intervention. Conversely those 
patients who did not receive pacemakers in studies may be disappointed and more inclined to 
report symptoms. Similar situations have also been encountered in the past with hypertrophic 
cardiomyopathy, where pacing was initially thought to improve functional status in open label 
studies(Nishimura et al., 1997). Similarly, atrial pacing was first reported to reduce atrial 
fibrillation, stroke, and death in patients with pacemakers(Gillis et al., 1999; Connolly et al., 
2000). However, randomized, controlled studies did not show the benefits that were seen in 
the open label studies in any of these situations(Gillis et al., 1999; Connolly et al., 2000; 
Nishimura et al., 1997). Hence interpretation of studies in pacing that are not randomized, 
double blind, placebo-controlled should be done with caution since there may be important 
placebo effects. The vasodepressor and cardioinhibitory components may vary in each patient 
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with different episodes and 50% to 83% of syncopal episodes may not have a cardioinhibitory 
component(Sheldon & Connolly, 2003). This may also explain why pacing does not seem to be 
of benefit in vasovagal syncope. Pacing alone may not be enough to overcome vasodepression.  
7. Ongoing studies 
Although the two blinded randomized trials are small (VPS II and SYNPACE), it seems 
pacing may not benefit most patients with vasovagal syncope. The ISSUE 2 study reported 
392 patients with recurrent syncope and an implantable loop recorder (ILR)(Brignole et al., 
2006). Specific treatment was then given to 53 patients based on the monitoring findings, of 
whom 47 received a pacemaker for asystole and 6 received anti-tachycardia treatments. A 
marked decrease in syncopal episodes was noted in the group that received specific 
treatment. In the 53 patients receiving specific treatment, the 1-year syncope recurrence rate 
was 10% compared to 41% in the patients without specific treatment. However the study is 
limited by lack of blinding and having only a minority of patients receiving specific 
treatment. To overcome the limitation of ISSUE 2, the ISSUE 3 study was designed 
(Brignole, 2007). Patients found to have asystolic pauses associated with syncope on ILR 
monitoring were randomized to pacemaker On or Off. This is a multicenter, randomized, 
placebo-controlled, prospective study of patients with a documented pause during syncope 
on an implantable loop recorder and then randomized to a pacemaker with pacing or only 
sensing. ISSUE 3 has finished recruitment and is now in the follow-up phase. The results of 
this study will help to clarify whether pacing may be of benefit in vasovagal syncope 
patients with prolonged asystolic pauses. As mentioned previously, initial studies also 
suggest that using a closed loop pacing (CLS) that detects contractility may be able to detect 
a neurocardiogenic episode early and provide pacing support better than a rate drop 
system(Kanjwal, Karabin, Kanjwal, & Grubb, 2010; Occhetta, Bortnik, & Vassanelli, 2003; 
Occhetta, Bortnik, Audoglio, & Vassanelli, 2004b). A randomized, prospective, double blind, 
cross over study (SCANSYNC) compared active (CLS pacing) to passive (VVI 30) pacing in 
patients with recurrent vasovagal syncope has been completed and is awaiting publication. 
8. Other treatment options in vasovagal syncope 
Other treatments for vasovagal syncope have also had similar findings with open label and 
observational studies showing benefit but double blind, randomized studies showing minimal 
benefit or no difference from placebo(Kuriachan, Sheldon, & Platonov, 2008). In patients with 
an identifiable prodrome there may be some benefit to using physical counterpressure 
maneuvers (PCM) which are safe and cost free(van et al., 2006). The maneuvers used are 
usually leg crossing with tensing of abdominal, buttock, and lower extremity muscles and/or 
gripping hands while abducting both arms. These maneuvers should be tried as first line 
treatments in patients with vasovagal syncope and an identifiable prodrome. Ensuring 
adequate volume repletion is important with salt and fluid intake. Various medications have 
also been studied, including beta-blockers, selective serotonin re-uptake inhibitors (SSRI), 
Fludrocortisone, and Midodrine. In general, no clear benefit has thus far been seen from 
studies with beta-blockers, SSRIs, and fludrocortisone(Kuriachan & Sheldon, 2008). The POST 
II study is comparing fludrocortisone to placebo in a randomized, double blind fashion and is 
in the follow-up phase (Raj, Rose, Ritchie, & Sheldon, 2006). Midodrine, a peripherally acting 
alpha-agonist, does seem to have some benefit in adults and children. Frequent dosing and 
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some side effects, such as supine hypertension, may limits its use(Kuriachan et al., 2008). POST 
IV will be a double blind, randomized, placebo controlled study comparing midodrine to 
placebo in patients with vasovagal syncope. 
The initial management approach to a patient with vasovagal syncope should include 
education about the condition, reassurance, and dietary intake (particularly salt and fluid). 
PCM should be taught to patients with a prodrome. If they still have frequent recurrent 
symptoms then medications attempts should be made. Pacing should be reserved as a last 
resort and ideally in patients documented with asystole during their syncopal episodes. A 
frank and open discussion should be held with the patient about the limited benefit that has 
been seen in studies for medications and pacing. Refer to Figure 4 for management 
approach for vasovagal syncope. 
 
 
Fig. 4. Pyramid scheme of treatment for vasovagal syncope. All patients should receive the 
basic interventions as appropriate. Currently limited evidence for medications and pacing, 
hence use should be limited in very select patients who have significant, recurrent episodes 
after the basic interventions. 
9. Carotid sinus hypersensitivity 
Carotid sinus hypersensitivity and association with syncope have been known for many 
years. Carotid sinus hypersensitivity (CSH) is defined as a fall in systolic BP > 50mmHg 
and/or asystolic pause > 3 seconds with carotid sinus massage. Carotid sinus syndrome is 
when CSH is associated with spontaneous syncope that can be reproduced with carotid 
sinus massage(CSM). Carotid sinus syncope tends to happen in elderly men and the 
prevalence increases with cardiovascular, cerebrovascular, and neurodegenerative 
disease(Claesson, Kristensson, Edvardsson, & Wahrborg, 2007). A fall from syncope can 
result in significant injuries given the older age of this patient population. Although there is 
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limited evidence, carotid sinus syncope has been believed to occur in the context head 
turning movements that may cause pressure on the carotid, such as shoulder checking in a 
car with shoulder seat belt putting pressure or wearing a tight collar. 
It is important to differentiate carotid sinus hypersensitivity from carotid sinus syndrome. A 
positive carotid sinus massage was noted in 32% of patients having an angiogram who had 
no history of carotid sinus syncope(Brown, Maloney, Smith, Haritzler, & Ilstrup, 1980). 
Asymptomatic carotid sinus hypersensitivity may be common in the elderly. Carotid sinus 
reflex helps with hemodynamic regulation. The vagal efferent signals increases cardiac 
vagal input resulting in lowering heart rate and peripheral vasodilation lowering blood 
pressure(LOWN & LEVINE, 1961). Hence an abnormal reflex can cause significant changes 
in blood pressure and heart rate which decreases brain perfusion and results in syncope. 
10. Carotid sinus massage 
Various protocols have been used for carotid sinus massage (Brignole et al., 2001). In one 
method, the carotid artery is firmly massaged at the anterior margin of the 
sternocleidmastoid at the cricoids cartilage level for up to 5 seconds, while the patient is in a 
supine position. If the first side does not yield a positive result then CSM is performed on 
the other side. Asystolic pause > 3 seconds (sinus pause or at times due to AV block), fall in 
BP > 50mmHg, and development of symptoms are necessary for a truly positive test. 
Abnormal responses can also be seen in patients with a history of spontaneous syncope. 
Some protocols use longer duration of massage to reproduce spontaneous symptoms, as 
well as both supine and upright positions (ensure patient safety in upright position). Heart 
rate changes can be readily seen on cardiac monitoring but a blood pressure drop is difficult 
to document without invasive monitoring (not usually practical) or noninvasive continuous 
digital plethysmography. CSM is contraindicated in patients with carotid bruits or history of 
prior stroke/TIA, due to concerns that the CSM may result in carotid plaque disruption and 
embolization resulting in a cerebrovascular event. Studies have looked at the safety of CSM, 
totaling over 5000 patients and found complication rates in the 0.1 – 0.2% range, of which 
most were transient neurological symptoms and full recovery was made except in two 
patients(Munro et al., 1994; Davies & Kenny, 1998).  
11. Pacing studies in carotid sinus syncope 
One of the first studies in carotid sinus syncope reported 70 patients with CSH and syncope, 
and found pacing to be very effective(Morley et al., 1982a). Subsequently a second study 
assessed 56 consecutive patients with CSH and syncope who had received no treatment (13 
patients), anticholinergic medications (20), and pacemaker implant (23). In this study, 
pacing was effective in preventing syncope but a high rate of spontaneous remission was 
also observed(Sugrue et al., 1986). Another study with 21 patients, in which 13 received 
pacemakers, found only minimal benefit with pacing(Huang, Ezri, Hauser, & Denes, 1988). 
However, none of the patients with pacemakers had recurrences of syncope and only one 
patient had recurrence in the no pacemaker group of eight patients, demonstrating a very 
low recurrence rate even without receiving treatment. Other observational studies also 
found benefits from pacing and are listed in Table 3(Brignole et al., 1991; Brignole, Menozzi, 
Lolli, Sartore, & Barra, 1988).Hence some benefit was observed with pacing in CSH and 
syncope in the initial studies, but there were high rates of spontaneous remission.  
www.intechopen.com
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
188 
Since many elderly patients who have syncope may not remember the details of the event and 
prodrome, they may present with a non-accidental fall. Hence it was thought that in many 
elderly patients, carotid sinus syncope might be responsible for non-accidental falls. This was 
first examined in the SAFE-PACE trial(Kenny et al., 2001). This open-label study included 175 
consecutive patients over the age of 50 with non-accidental falls attending an accident and 
emergency facility. Those with carotid sinus hypersensitivity were randomized to rate drop 
dual chamber pacemaker or standard treatment. Paced patients were significantly less likely to 
fall (odds ratio 0.42) and reduced injurious event by 70%. SAFE-PACE 2 was a double blind, 
randomized study done to assess this(Daniel, Steen, Seifer, & Kenny, 2010). 141 patients with 
unexplained falls and cardioinhibitory carotid sinus hypersensitivity were randomized to a 
rate responsive pacemaker or implantable loop recorder. No significant reduction was seen in 
the pacemaker group, but this small sample size led to an underpowered study. Again, due to 
concerns of the open-label nature of the initial SAFE-PACE, a randomized study was 
conducted in which 25 patients received pacemakers but was randomized to pacemaker On 
(DDD) or Off (ODO)(Parry, Steen, Bexton, Tynan, & Kenny, 2009). This was a double blind 
study with a cross over design. There was a mean of 3.48 falls in the ODO mode and 4.04 in 
the DDD mode. Survival analysis showed no significant differences in time to first fall between 
the two groups (Figure 5). Hence no benefit was seen with pacing in this group for fall 
reduction. Further supporting the placebo effect in this study was the fall reduction that was 
seen in both groups, pacemaker On or Off, in the first six months after implant. However, this 
study was underpowered and should be interpreted with caution. Hence the initial impressive 
benefits seen in SAFE-PACE may be due to a placebo effect similar to the open-label vasovagal 
pacing studies.  
 
 
Fig. 5. Survival analysis (treating each group as independent samples) showed no significant 
differences in time to first fall between DDD and ODO modes. P=0.57. Figure from Parry et 
al. 2009. 
www.intechopen.com
 
Role of Pacing in Neurally Mediated Syncope 
 
189 
Study (year) 
Number of 
Patients 
Methodology Study Arms Results 
Sugrue et al. (1986) 56 Observational 
13 no treatment  23 
pacemaker   20 
anticholinergics 
Pacing was effective 
but high rate of 
spontaneous 
remission 
Morley et al. (1982) 70 Observational 
54 patients VVI  13 
patients DVI  18 
patients DDD    
89% asymptomatic 
with pacing 
Huang et al. (1988 ) 21 Observational 
13 with pacemaker 8 
with no implant 
Pacing found to be 
beneficial. However 
only one patient had 
recurrence (in no 
pacer group) 
Brignole et al. (1991) 60 
Observational 
Crossover 
26 with DDD   34 
with VVI 
DDD found to have 
less symptoms 
overall 
Brignole et al.(1988) 35 Observational 
19 no implant    11 
with VVI    5 with 
DDD 
Pacing prevented 
syncope recurrence 
SAFEPACE 1 (2001) 175 Open label 
87 with pacemaker 88 
no implant 
Pacing reduced falls 
and minimal 
reduction of syncope 
SAFEPACE 2 (2010) 141 Double blind 
71 with pacemaker 70 
with loop recorder 
No significant 
reduction in falls 
seen 
Parry et al. (2009) 25 
Double blind 
Crossover 
25 DDD and 
crossover to ODO 
Pacing had no effect 
of falls 
Table 3. Pacing studies in context of Carotid Sinus Hypersensitivity, Syncope, and Falls. 
Although only a few small studies have shown benefit, pacing has generally been felt to be 
beneficial in this condition, especially in elderly patients with a predominantly 
cardioinhibitory response to CSM and present with symptoms suggestive of carotid sinus 
syncope(Brignole, Menozzi, Lolli, Bottoni, & Gaggioli, 1992; Morley et al., 1982b; Claesson et 
al., 2007; Moya et al., 2009). Management should also include volume repletion and 
recommendations on avoiding situations that may cause syncope, such as tight collars and 
ties. Volume expanders and vasopressors may also be helpful but usually are limited due to 
problems with heart failure and hypertension that is common in the elderly population. 
12. Conclusion 
Initial steps in the management of vasovagal syncope should include education about the 
diagnosis and reassurance. Patients should be instructed on liberal intake of salt and fluid. 
Counterpressure maneuvers should be taught to patients with a prodrome. If they still have 
frequent recurrent symptoms, then medications attempts should be made. Pacing should be 
reserved as a last resort and ideally in patients documented with asystole during their 
syncopal episodes. For patients with carotid sinus syncope, pacing should be considered. 
Additional management should also include volume repletion and recommendations on 
avoiding situations that may cause syncope. 
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